ArticleInternational journal of rheumatic diseases2017

Response to Jani et al. A prospective, randomized, doubleblind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.

Barry KanePubMed ↗Publisher ↗

No numbers read from the abstract.